High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer
, , , , , , , , und
16. Juni 2017
Über diesen Artikel
Artikel-Kategorie: Research Article
Online veröffentlicht: 16. Juni 2017
Seitenbereich: 324 - 330
Eingereicht: 17. Jan. 2017
Akzeptiert: 14. Mai 2017
DOI: https://doi.org/10.1515/raon-2017-0023
Schlüsselwörter
© 2017 Takashi Ono, Tomonori Yabuuchi, Tatsuya Nakamura, Kanako Kimura, Yusuke Azami, Katsumi Hirose, Motohisa Suzuki, Hitoshi Wada, Yasuhiro Kikuchi, Kenji Nemoto
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
Figure 2
Figure 3
Overall survival of central lung cancer
| Number of patients | Median follow up time | treatment | Overall survival rate | All grade 3-5 toxicities | |
|---|---|---|---|---|---|
| 9 | 26.5 months | SBRT | 50% (2-year) | 33% | |
| 125 | 17.4 months | SBRT | 64% (2-year) | 8% | |
| 34 | 18.4 months | SBRT | 63.2% (2-year) | 3% | |
| 80 | 47 months | SBRT | 53% (3-year) | 6.4% | |
| 33 | 48 months | PBT | Not applicable | 0 | |
| present study | 20 | 27.5 months | PBT | 73.8% (2-year) | 0 |
Toxicities
| Toxicities | Grade 0 | Grade 1 | Grade 2 | Grade 3 - 5 |
|---|---|---|---|---|
| 0 | 18 (90%) | 2 (1 0%) | 0 | |
| 20 (100%) | 0 | 0 | 0 | |
| 16 (80%) | 4 (20%) | 0 | 0 | |
| 15 (75%) | 3 (15%) | 2 (10%) | 0 |
The patient characteristics (n = 20)
| Characteristics | Patients |
|---|---|
| Age (years) | |
| Median (range) | 75 (63–90) |
| Gender | |
| Male | 17 (85%) |
| Female | 3 (15%) |
| Performance status | |
| 0 | 8 (40%) |
| 1 | 8 (40%) |
| 2 | 4 (20%) |
| Charlson Index | |
| 0 | 5 (25%) |
| 1 | 6 (30%) |
| 2 | 7 (35%) |
| 3 | 2 (10%) |
| Follow-up time (months) | |
| Median (range) | 27.5 (12-72) |
| Chronic obstructive pulmonary disease | |
| Yes | 9 (45%) |
| No | 11 (55%) |
| T category Numbers correspond to the tumor-node-metastasis system of classification (International Union Against Cancer criteria) |
|
| T1 | 4 (20%) |
| T2 | 11 (55%) |
| T3 | 4 (20%) |
| T4 | 1 (5%) |
| Stage Numbers correspond to the tumor-node-metastasis system of classification (International Union Against Cancer criteria) |
|
| I | 15 (75%) |
| II | 4 (20%) |
| III | 1 (5%) |
| Tumor location | |
| Right upper lobe | 7 (35%) |
| Right middle lobe | 2 (10%) |
| Right lower lobe | 6 (30%) |
| Left upper lobe | 3 (15%) |
| Left lower lobe | 2 (10%) |
| Histopathology | |
| Squamous cell carcinoma | 8 (40%) |
| Adenocarcinoma | 5 (25%) |
| Clinical malignancy | 7 (35%) |
| Diameter of lung tumor (mm) | |
| Median (range) | 39.5 (24-81) |